Quick Overview of United Therapeutics

By Naomi Wentworth • Wednesday, December 20 16:53 • Permanent Link

United Therapeutics sank -6.1% today, compared to the S&P 500's day change of -1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

United Therapeutics has moved -12.2% over the last year, and the S&P 500 logged a change of 22.9%
UTHR has an average analyst rating of buy and is -21.9% away from its mean target price of $288.73 per share
Its trailing earnings per share (EPS) is $18.14
United Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 12.4 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $22.07 and its forward P/E ratio is 10.2
The company has a Price to Book (P/B) ratio of 1.85 in contrast to the S&P 500's average ratio of 2.95
United Therapeutics is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
UTHR has reported YOY quarterly earnings growth of 9.6% and gross profit margins of 0.9%
The company has a free cash flow of $592.65 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.